Table 4.

Baseline type-specific HPV seropositivity and risk of new infection with HPV group viruses over follow-up by HIV serostatus, HERS

HPV serology/HPV group by PCR/HPV serostatus*HIV-negative
HIV-positive
Total no.No. (%) PCR positiveRelative risk (95% CI)§Total no.No. (%) PCR positiveRelative risk (95% CI)
HPV 16
    16 Group
        Seronegative19329 (15.0%)127571 (25.8%)
        Seropositive16924 (14.2%)1.02 (0.59,1.78)30895 (30.8%)1.10 (0.80, 1.52)
    18 Group
        Seronegative20021 (10.5%)33176 (23.0%)
        Seropositive18114 (7.7%)0.77 (0.39, 1.53)35880 (22.4%)0.86 (0.62, 1.19)
    Other group
        Seronegative16775 (44.9%)204134 (65.7%)
        Seropositive15467 (43.5%)0.97 (0.68, 1.38)210145 (69.1%)1.01 (0.77, 1.31)
HPV 18
    16 Group
        Seronegative22032 (14.6%)23249 (21.1%)
        Seropositive13020 (15.4%)0.97 (0.55 1.71)31198 (31.5%)1.59 (1.11, 2.27)
    18 Group
        Seronegative22823 (10.1%)27254 (19.9%)
        Seropositive1439 (6.3%)0.58 (0.27, 1.27)36087 (24.2%)1.21 (0.85, 1.72)
    Other group
        Seronegative18879 (42.0%)173107 (61.9%)
        Seropositive12660 (47.6%)1.16 (0.81, 1.66)207146 (70.5%)1.28 (0.96, 1.69)
HPV 31
    16 Group
        Seronegative14829 (19.6%)12929 (22.5%)
        Seropositive18622 (11.8%)0.61 (0.35, 1.07)416132 (31.7%)1.25 (0.83, 1.90)
    18 Group
        Seronegative15216 (10.5%)14231 (21.8%)
        Seropositive20118 (9.0%)0.89 (0.45, 1.75)486118 (24.3%)0.92 (0.61, 1.38)
    Other group
        Seronegative13061 (46.9%)9152 (57.1%)
        Seropositive17176 (44.4%)0.99 (0.69, 1.42)294213 (72.5%)1.45 (1.04, 2.04)
HPV 35
    16 Group
        Seronegative20238 (18.8%)28274 (26.2%)
        Seropositive12715 (11.8%)0.58 (0.31, 1.06)24476 (31.2%)1.14 (0.82, 1.59)
    18 Group
        Seronegative21120 (9.5%)31463 (20.1%)
        Seropositive13914 (10.1%)1.06 (0.53, 2.12)30278 (25.8%)1.25 (0.89, 1.76)
    Other group
        Seronegative17169 (40.4%)199128 (64.3%)
        Seropositive11954 (45.4%)1.03 (0.71, 1.52)178127 (71.4%)1.07 (0.81, 1.43)
HPV 45
    16 Group
        Seronegative16421 (12.8%)20956 (26.8%)
        Seropositive15423 (14.9%)1.18 (0.65, 2.15)30692 (30.1%)1.16 (0.82, 1.64)
    18 Group
        Seronegative17519 (10.9%)24254 (22.3%)
        Seropositive16612 (7.2%)0.64 (0.31, 1.32)35884 (23.5%)0.98 (0.69, 1.40)
    Other group
        Seronegative14357 (39.9%)154100 (64.9%)
        Seropositive14664 (43.8%)1.18 (0.81, 1.73)211149 (70.6%)1.06 (0.79, 1.41)
  • * Women with indeterminate serologic results were excluded from analysis.

  • Women with an infection of any HPV type in the group at the baseline visit were excluded from analysis.

  • Women PCR-positive for viruses within the HPV group. HPV 16 group includes types 16, 31, 33, 35, 52, and 58; HPV 18 group includes types 18, 39, 45, 59, and 68; “other” HPV group includes types 6, 11, 26, 40, 42, 51, 53, 54, 55, 56, 66, 73, 82, 83, 84, and nontypeables.

  • § Covariates in the Cox proportional hazards model included baseline serology status (binary, excluding indeterminate serology), time-varying number of male sexual partners in the last 6 months at each study visit, and baseline CD4 (for HIV-positive women only).